Stay updated with breaking news from Sclerosis Complex. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZTALMY® first quarter U.S. net product revenue of $3.3 million Now planning to conduct an interim analysis for the Phase 3 refractory status epilepticus trial in the second half of... | May 11, 2023
ZTALMY® U.S. net product revenue of $2.3 million for the fourth quarter of 2022 and $2.9 million for the fiscal year ended December 31, 2022Company expects ZTALMY U.S. net product revenues of between $15 million and $17 million for the fiscal year ending December 31, 2023Second generation oral formulation developmen...
ZTALMY® can now be prescribed by healthcare professionals in the U.S.Second generation ganaxolone formulation demonstrates encouraging results in Phase 1 study in healthy volunteers and supports further clinical developmentMarinus’ Phase 2 refractory status epilepticus (RSE) trial data published in Epilepsia in June...
Press release content from Business Wire. The AP news staff was not involved in its creation.
With the help of cerebral organoids, IMBA scientists were able to ascertain that Tuberous Sclerosis, a rare neurodevelopmental genetic disorder